SARTORIUS STEDIM BIOTECH (56S1.DE) Fundamental Analysis & Valuation

FRA:56S1 • FR0013154002

Current stock price

181.8 EUR
+0.8 (+0.44%)
Last:

This 56S1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. 56S1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 56S1 was profitable.
  • In the past year 56S1 had a positive cash flow from operations.
  • In the past 5 years 56S1 has always been profitable.
  • In the past 5 years 56S1 always reported a positive cash flow from operatings.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • 56S1 has a Return On Assets of 3.33%. This is in the lower half of the industry: 56S1 underperforms 61.11% of its industry peers.
  • 56S1 has a Return On Equity (6.50%) which is in line with its industry peers.
  • With a Return On Invested Capital value of 6.11%, 56S1 perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for 56S1 is below the industry average of 9.03%.
  • The last Return On Invested Capital (6.11%) for 56S1 is above the 3 year average (5.23%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROIC 6.11%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.96%, 56S1 is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
  • 56S1's Profit Margin has declined in the last couple of years.
  • 56S1 has a Operating Margin of 17.72%. This is in the better half of the industry: 56S1 outperforms 66.67% of its industry peers.
  • 56S1's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 45.33%, 56S1 is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 56S1 has declined.
Industry RankSector Rank
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. 56S1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 56S1 is destroying value.
  • The number of shares outstanding for 56S1 remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, 56S1 has more shares outstanding
  • 56S1 has a better debt/assets ratio than last year.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • 56S1 has an Altman-Z score of 4.04. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
  • 56S1 has a better Altman-Z score (4.04) than 72.22% of its industry peers.
  • 56S1 has a debt to FCF ratio of 8.69. This is a slightly negative value and a sign of low solvency as 56S1 would need 8.69 years to pay back of all of its debts.
  • 56S1 has a Debt to FCF ratio (8.69) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.49 indicates that 56S1 is not too dependend on debt financing.
  • 56S1's Debt to Equity ratio of 0.49 is fine compared to the rest of the industry. 56S1 outperforms 72.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Altman-Z 4.04
ROIC/WACC0.71
WACC8.6%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.3 Liquidity

  • 56S1 has a Current Ratio of 1.02. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
  • 56S1's Current ratio of 1.02 is on the low side compared to the rest of the industry. 56S1 is outperformed by 61.11% of its industry peers.
  • A Quick Ratio of 0.53 indicates that 56S1 may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.53, 56S1 is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.53
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. 56S1.DE Growth Analysis

3.1 Past

  • 56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.71%, which is quite impressive.
  • 56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.13% yearly.
  • 56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 6.74%.
  • The Revenue has been growing by 9.21% on average over the past years. This is quite good.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%

3.2 Future

  • 56S1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.04% yearly.
  • The Revenue is expected to grow by 11.26% on average over the next years. This is quite good.
EPS Next Y17.04%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
EPS Next 5Y19.04%
Revenue Next Year7.37%
Revenue Next 2Y8.99%
Revenue Next 3Y9.53%
Revenue Next 5Y11.26%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. 56S1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 41.32, which means the current valuation is very expensive for 56S1.
  • 56S1's Price/Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 72.22% of the companies in the same industry.
  • 56S1 is valuated expensively when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 35.30, the valuation of 56S1 can be described as expensive.
  • Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
  • 56S1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 38.20.
Industry RankSector Rank
PE 41.32
Fwd PE 35.3
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 72.22% of the companies in the same industry.
  • 56S1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 59.18
EV/EBITDA 23.49
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 56S1 does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as 56S1's earnings are expected to grow with 18.07% in the coming years.
PEG (NY)2.43
PEG (5Y)36.63
EPS Next 2Y18.3%
EPS Next 3Y18.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 56S1.DE Dividend Analysis

5.1 Amount

  • 56S1 has a yearly dividend return of 0.41%, which is pretty low.
  • 56S1's Dividend Yield is comparable with the industry average which is at 0.52.
  • With a Dividend Yield of 0.41, 56S1 pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.41%

5.2 History

  • On average, the dividend of 56S1 grows each year by 15.19%, which is quite nice.
Dividend Growth(5Y)15.19%
Div Incr Years0
Div Non Decr Years2
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1

5.3 Sustainability

  • 25.24% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
  • The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.24%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

56S1.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS STEDIM BIOTECH

FRA:56S1 (4/15/2026, 7:00:00 PM)

181.8

+0.8 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners11.99%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.69B
Revenue(TTM)2.97B
Net Income(TTM)265.80M
Analysts84.21
Price Target227.19 (24.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.41%
Yearly Dividend0.69
Dividend Growth(5Y)15.19%
DP25.24%
Div Incr Years0
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.48%
Min EPS beat(2)-12.72%
Max EPS beat(2)-2.24%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-12.72%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.28%
EPS beat(12)3
Avg EPS beat(12)-11.72%
EPS beat(16)3
Avg EPS beat(16)-14.26%
Revenue beat(2)0
Avg Revenue beat(2)-4.06%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)-3.94%
Revenue beat(4)2
Avg Revenue beat(4)-1.07%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)3.52%
Revenue beat(8)4
Avg Revenue beat(8)-1.65%
Revenue beat(12)5
Avg Revenue beat(12)-1.63%
Revenue beat(16)6
Avg Revenue beat(16)-1.17%
PT rev (1m)-8.16%
PT rev (3m)-5.61%
EPS NQ rev (1m)-1.27%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.14%
EPS NY rev (3m)-4.1%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-1.2%
Valuation
Industry RankSector Rank
PE 41.32
Fwd PE 35.3
P/S 5.96
P/FCF 59.18
P/OCF 25.56
P/B 4.33
P/tB N/A
EV/EBITDA 23.49
EPS(TTM)4.4
EY2.42%
EPS(NY)5.15
Fwd EY2.83%
FCF(TTM)3.07
FCFY1.69%
OCF(TTM)7.11
OCFY3.91%
SpS30.49
BVpS42.03
TBVpS-3.39
PEG (NY)2.43
PEG (5Y)36.63
Graham Number64.5042 (-64.52%)
Profitability
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROCE 8%
ROIC 6.11%
ROICexc 6.56%
ROICexgc 23.58%
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
FCFM 10.08%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
ROICexc(3y)5.56%
ROICexc(5y)12.62%
ROICexgc(3y)18.67%
ROICexgc(5y)31.48%
ROCE(3y)6.85%
ROCE(5y)15.55%
ROICexgc growth 3Y-18%
ROICexgc growth 5Y-10.32%
ROICexc growth 3Y-31.81%
ROICexc growth 5Y-17.24%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Debt/EBITDA 2.39
Cap/Depr 123.61%
Cap/Sales 13.25%
Interest Coverage 3.42
Cash Conversion 82.03%
Profit Quality 112.49%
Current Ratio 1.02
Quick Ratio 0.53
Altman-Z 4.04
F-Score7
WACC8.6%
ROIC/WACC0.71
Cap/Depr(3y)145.19%
Cap/Depr(5y)180.27%
Cap/Sales(3y)14.18%
Cap/Sales(5y)13.22%
Profit Quality(3y)157.37%
Profit Quality(5y)116.81%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
EPS Next Y17.04%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
EPS Next 5Y19.04%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%
Revenue Next Year7.37%
Revenue Next 2Y8.99%
Revenue Next 3Y9.53%
Revenue Next 5Y11.26%
EBIT growth 1Y41.93%
EBIT growth 3Y-20.72%
EBIT growth 5Y1.39%
EBIT Next Year53.61%
EBIT Next 3Y26%
EBIT Next 5Y22.89%
FCF growth 1Y-37.09%
FCF growth 3Y18.06%
FCF growth 5Y3.02%
OCF growth 1Y-15.08%
OCF growth 3Y4.17%
OCF growth 5Y10.67%

SARTORIUS STEDIM BIOTECH / 56S1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.


Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.


What is the profitability of 56S1 stock?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.


What are the PE and PB ratios of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 41.32 and the Price/Book (PB) ratio is 4.33.


Can you provide the dividend sustainability for 56S1 stock?

The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.24%.